Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2021 16:05 ET | Source: Gritstone bio, Inc.

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
September 20, 2021 07:01 ET | Source: Gritstone bio, Inc.

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

GRT-R910, a self-amplifying mRNA (SAM) SARS-CoV-2 vaccine, delivers antigens from both the spike protein and highly conserved non-spike proteins for broad protection across variants Induction...
September 17, 2021 07:02 ET | Source: Gritstone bio, Inc.

Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

SLATE version (v) 1, Gritstone’s “off the-shelf" neoantigen immunotherapy (including KRAS, TP53 mutations), elicited multiple molecular responses and an unconfirmed RECIST radiologic response in...
September 17, 2021 07:01 ET | Source: Gritstone bio, Inc.

Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent

GRANITE individualized immunotherapy demonstrates objective evidence of efficacy in end-stage colorectal cancer (CRC) patients (3rd line or greater) who have “cold” tumors at baseline 44% molecular...
September 16, 2021 16:01 ET | Source: Gritstone bio, Inc.

Gritstone Announces Private Placement Financing of $55.0 Million

EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease...